Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-04-25 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于召开2015年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2015 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It includes information about the meeting date, location, voting procedures (both onsite and online), agenda items to be discussed and voted on, registration methods, and proxy authorization forms. The document does not contain the actual annual report, financial statements, or audit reports but rather serves as an official notification to shareholders about the AGM and the matters to be considered. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices about the AGM itself. The document length is 7302 characters, which is consistent with a detailed AGM notice rather than a full annual report or audit report. Therefore, the correct classification is AGM Information (AGM-R).
2016-04-25 Chinese
关于部分募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the delay of certain investment projects funded by the company's raised capital. It details the original and adjusted timelines for project completion, reasons for the delay, and confirms that the investment amounts and project scope remain unchanged. It includes opinions from the board, independent directors, supervisory board, and the sponsoring institution, confirming compliance with regulatory requirements and no adverse impact on shareholders. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about capital project progress and changes. The document length is 2857 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to updates on the use and progress of raised funds and capital projects.
2016-04-25 Chinese
关于2015年度募集资金实际存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the actual storage and usage of funds raised by 福安药业（集团）股份有限公司 for the fiscal year 2015. It includes specifics on the amount raised, usage of funds, changes in investment projects, management of funds, and compliance with regulatory requirements. The document references approvals from the China Securities Regulatory Commission and includes detailed financial tables and project updates. It is not a brief announcement or a certification but a comprehensive report on fundraising and capital usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and operational details about the use of raised capital, not just an announcement or summary.
2016-04-25 Chinese
2015年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2015年度监事会工作报告" which translates to the "2015 Supervisory Board Work Report". It details the supervisory board's activities, meetings, and oversight of the company's operations, financial status, internal controls, and compliance with laws and regulations during the 2015 fiscal year. It includes references to financial audits, internal control evaluations, and supervisory opinions on company governance and financial management. The document is a comprehensive report on the supervisory board's work and oversight for the year 2015, which aligns with the characteristics of an Audit Report / Information (AR) filing. It is not an Annual Report (10-K) as it focuses on supervisory board activities and audit-related oversight rather than a full company annual report. It is also not a short announcement or certification, so it does not fall under RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2015
2016-04-25 Chinese
独立董事2015年度述职报告（蔡开勇）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company for the year 2015. It includes descriptions of attendance at board and shareholder meetings, opinions on various company matters, participation in committees, investigations, and efforts to protect investor rights. The content is focused on governance and the independent director's duties and opinions rather than financial statements or audit results. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is a management/board-related report specifically from an independent director about their activities and opinions during the year. This fits best under Board/Management Information (MANG) as it relates to board activities and management oversight. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2016-04-25 Chinese
2015年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the fiscal year 2015 of 福安药业（集团）股份有限公司. It includes an auditor's opinion, detailed financial statements such as consolidated and parent company balance sheets, income statements, cash flow statements, and changes in equity. The presence of an auditor's report with registration numbers and signatures from certified public accountants, along with comprehensive financial data for the full fiscal year, clearly indicates this is a standalone audit report. It is not merely an announcement or a certification letter, but a full audit report with financial statements and notes. Therefore, the document fits the category of Audit Report / Information (AR). FY 2015
2016-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.